Study of a new treatment for advanced bile duct cancer
Part of Cancer clinical trials.
This trial is testing a new treatment called HCA nano for a type of bile duct cancer that cannot be removed by surgery and has not spread. It is for patients whose cancer did not grow after standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with perihilar cholangiocarcinoma that is locally advanced and inoperable.
- Your cancer has not spread to distant organs.
- You have received at least 3 cycles of standard chemotherapy and your cancer did not progress.
- You have not had any prior systemic treatment for advanced disease, such as targeted therapy or immunotherapy.
- You have not been treated for another cancer (except certain skin cancers or cervical cancer in situ).
- You have not taken EGFR inhibitors (like erlotinib or cetuximab) within 30 days before starting the study.
- You have adequate organ and bone marrow function, as shown by blood tests.
- You have a life expectancy of at least 3 months.
- If you can become pregnant or father a child, you agree to use effective contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a treatment plan that first delivers chemotherapy directly into the liver (through a thin tube) along with standard IV chemotherapy. The goal is to shrink the tumor enough to allow for surgery or less aggressive treatment later. It is for people with bile duct or gallbladder cancer that has not spread far.
This trial tests a combination of three treatments—chemotherapy delivered directly to the liver, plus two immunotherapy drugs—for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment and is safe for patients.
This trial tests a combination of drugs to treat advanced bile duct cancer that cannot be removed by surgery. The treatment may help shrink tumors and improve outcomes.
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
Hear when a new IRE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.